Literature DB >> 8656679

The CD30 ligand and CD40 ligand regulate CD54 surface expression and release of its soluble form by cultured Hodgkin and Reed-Sternberg cells.

H J Gruss1, I Scheffrahn, G Hubinger, J Duyster, F Hermann.   

Abstract

The membrane-bound proteins CD30 ligand (CD30L), CD40L and 4-1BBL are members of the tumor necrosis factor (TNF) superfamily. They are expressed mainly by activated T cells. Primary and cultured Hodgkin and Reed-Sternberg (H-RS) cells, regarded as the malignant components of Hodgkin's disease (HD), display high levels of the counter-receptors for these ligands, ie CD30, CD40 and 4-1BB. CD30L and CD40L are known to share some biological activities that can be linked to the unbalanced secretion of cytokines seen in HD. In addition, cell contact-dependent molecules such as adhesion or activation antigens are critically involved in T cell/H-RS cell interactions. Primary and cultured H-RS cells frequently overexpress intercellular adhesion molecule-1 (ICAM-1/CD54), BB-1 (B7-1/CD80) and B70/B7-2 (CD86). Here we show that CD30L and CD40L, but not 4-1BBL upregulate CD54 expression by cultured H-RS cells on the mRNA and protein level, as a result of transcriptional gene activation. Furthermore, enhanced CD54 surface expression by these cells is accompanied by increased shedding of surface-bound CD54, as evidenced by high levels of the 82 kDa soluble (s) CD54 form detectable in culture supernatants after specific stimulation. Addition of CD30L in combination with CD40L to cultured H-RS cells additively enhanced CD54 surface expression and its shedding. These results may give a plausible explanation why sCD54 serum levels are increased in patients with HD.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8656679

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  4 in total

1.  CD137 is expressed in follicular dendritic cell tumors and in classical Hodgkin and T-cell lymphomas: diagnostic and therapeutic implications.

Authors:  Matthew W Anderson; Shuchun Zhao; Aharon G Freud; Debra K Czerwinski; Holbrook Kohrt; Ash A Alizadeh; Roch Houot; Denize Azambuja; Irene Biasoli; José Carlos Morais; Nelson Spector; Hernan F Molina-Kirsch; Roger A Warnke; Ronald Levy; Yasodha Natkunam
Journal:  Am J Pathol       Date:  2012-09       Impact factor: 4.307

Review 2.  The role of T cells in the microenvironment of Hodgkin lymphoma.

Authors:  Frederik Wein; Ralf Küppers
Journal:  J Leukoc Biol       Date:  2015-08-28       Impact factor: 4.962

Review 3.  Hodgkin lymphoma: an update on its biology with new insights into classification.

Authors:  Haresh Mani; Elaine S Jaffe
Journal:  Clin Lymphoma Myeloma       Date:  2009-06

4.  Epstein-Barr virus expression in Hodgkin's disease in relation to patient characteristics, serum factors and blood lymphocyte function.

Authors:  U Axdorph; A Porwit-MacDonald; J Sjöberg; G Grimfors; M Ekman; W Wang; P Biberfeld; M Björkholm
Journal:  Br J Cancer       Date:  1999-12       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.